Verdence Capital Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $356K | Sell |
6,442
-23,046
| -78% | -$1.25M | 0.02% | 496 |
|
|
2025
Q4 | $1.45M | Sell |
29,488
-5,099
| -15% | -$238K | 0.09% | 217 |
|
|
2025
Q3 | $1.51M | Buy |
34,587
+486
| +1% | +$19K | 0.09% | 226 |
|
|
2025
Q2 | $1.31M | Buy |
34,101
+28,123
| +470% | +$1.07M | 0.09% | 220 |
|
|
2025
Q1 | $232K | Buy |
5,978
+55
| +0.9% | +$2.01K | 0.02% | 595 |
|
|
2024
Q4 | $200K | Sell |
5,923
-900
| -13% | -$32.4K | 0.02% | 610 |
|
|
2024
Q3 | $279K | Buy |
6,823
+1,402
| +26% | +$57.4K | 0.02% | 541 |
|
|
2024
Q2 | $209K | Sell |
5,421
-1,006
| -16% | -$42.3K | 0.02% | 567 |
|
|
2024
Q1 | $276K | Sell |
6,427
-154
| -2% | -$6.35K | 0.03% | 501 |
|
|
2023
Q4 | $244K | Sell |
6,581
-656
| -9% | -$23.6K | 0.02% | 512 |
|
|
2023
Q3 | $262K | Buy |
7,237
+473
| +7% | +$16.8K | 0.03% | 480 |
|
|
2023
Q2 | $241K | Buy |
+6,764
| New | +$243K | 0.03% | 479 |
|
|
2022
Q3 | – | Sell |
-4,220
| Closed | -$230K | – | 532 |
|
|
2022
Q2 | $230K | Buy |
4,220
+10
| +0.2% | +$552 | 0.03% | 453 |
|
|
2022
Q1 | $229K | Buy |
4,210
+36
| +0.9% | +$1.96K | 0.03% | 474 |
|
|
2021
Q4 | $230K | Sell |
4,174
-998
| -19% | -$51.9K | 0.03% | 463 |
|
|
2021
Q3 | $247K | Buy |
5,172
+492
| +11% | +$24.7K | 0.03% | 427 |
|
|
2021
Q2 | $233K | Sell |
4,680
-595
| -11% | -$28.6K | 0.03% | 429 |
|
|
2021
Q1 | $235K | Sell |
5,275
-48
| -0.9% | -$2.18K | 0.04% | 396 |
|
|
2020
Q4 | $245K | Sell |
5,323
-12,009
| -69% | -$552K | 0.05% | 342 |
|
|
2020
Q3 | $815K | Sell |
17,332
-3,899
| -18% | -$195K | 0.19% | 128 |
|
|
2020
Q2 | $1.08M | Sell |
21,231
-1,902
| -8% | -$97.6K | 0.27% | 101 |
|
|
2020
Q1 | $1.1M | Sell |
23,133
-1,442
| -6% | -$76.9K | 0.33% | 86 |
|
|
2019
Q4 | $1.44M | Sell |
24,575
-947
| -4% | -$52.7K | 0.35% | 76 |
|
|
2019
Q3 | $1.36M | Sell |
25,522
-996
| -4% | -$51.2K | 0.38% | 75 |
|
|
2019
Q2 | $1.33M | Sell |
26,518
-6,352
| -19% | -$319K | 0.38% | 78 |
|
|
2019
Q1 | $1.72M | Buy |
32,870
+3,126
| +11% | +$156K | 0.47% | 66 |
|
|
2018
Q4 | $1.42M | Sell |
29,744
-8,382
| -22% | -$413K | 0.4% | 67 |
|
|
2018
Q3 | $1.91M | Sell |
38,126
-7,321
| -16% | -$372K | 0.47% | 55 |
|
|
2018
Q2 | $2.29M | Sell |
45,447
-6,546
| -13% | -$330K | 0.56% | 52 |
|
|
2018
Q1 | $2.54M | Buy |
51,993
+13,275
| +34% | +$618K | 0.61% | 44 |
|
|
2017
Q4 | $1.72M | Buy |
+38,718
| New | +$1.79M | 0.41% | 52 |
|
Other funds holding GSK
JEST
Verdence Capital Advisors's GSK Position: Q1 2026 in Review
Verdence Capital Advisors reduced its GSK (GSK) stake by 78% in Q1 2026, selling an estimated $1.25M and leaving 6,442 shares worth $356K. The position accounts for 0.02% of the portfolio, ranked #496.
Verdence Capital Advisors first reported a position in GSK in Q4 2017 and has held it in 31 quarters since. The position peaked at $2.54M in Q1 2018. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Verdence Capital Advisors held 6,442 shares of GSK worth $356K as of Q1 2026.
- Verdence Capital Advisors sold 23,046 GSK shares in Q1 2026, an estimated $1.25M.
- GSK made up 0.02% of Verdence Capital Advisors's portfolio in Q1 2026, its #496 holding.
- Verdence Capital Advisors first reported a position in GSK in Q4 2017 and has held it in 31 quarters since.
- Verdence Capital Advisors's GSK position peaked at $2.54M in Q1 2018.
- 1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Verdence Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.